Seminars in Oncology
Volume 31, Issue 1 , Pages 90-119, February 2004

Apoptosis in cancer—implications for therapy☆

  • Henning Schulze-Bergkamen

      Affiliations

    • Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • ,
  • Peter H Krammer

      Affiliations

    • Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • Corresponding Author InformationAddress reprint requests to Peter H. Krammer, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany

Abstract 

Resistance towards apoptosis is a key factor for the survival of a malignant cell. Cancer results if there is too little apoptosis and cells grow faster and live longer than normal cells. In addition, defects in apoptosis signaling contribute to drug resistance of tumor cells. Thus, one of the main goals for oncologic treatment is to overcome resistance of tumor cells towards apoptosis. The exciting challenge in oncology is to translate the growing knowledge of apoptotic pathways into clinical applications. In this review we address the role of apoptosis signaling in tumorigenesis and drug resistance of tumor cells and discuss therapeutic approaches interfering with apoptosis pathways.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Supported by the Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe/Dr Mildred Scheel-Stiftung, Tumorzentrum Heidelberg/Mannheim, the Medical Faculty of the University of Heidelberg, and the National Cancer Center, Bethesda, MD.

PII: S0093-7754(03)00568-2

doi:10.1053/j.seminoncol.2003.11.006

Seminars in Oncology
Volume 31, Issue 1 , Pages 90-119, February 2004

Article Tools

* Image Usage & Resolution